See Why FSD Pharma Terminated COVID-19 Trial

  • FSD Pharma Inc HUGE will terminate the Phase 2 trial of ultra-micronized palmitoylethanolamide (PEA), or FSD-201, for COVID-19.
  • FSD-201 works by stabilizing mast cells and down-regulates the pro-inflammatory cytokines to effectuate an anti-inflammatory response.
  • It is also known to target the CB2 receptors of the human body's endocannabinoid system.
  • FSD Pharma has previously completed a Phase 1 safety and tolerability study for FSD-201 and the compound to be safe with no serious adverse side effects. 
  • As previously disclosed, FSD Pharma retained Bloom Burton Securities Inc to undertake viability & commercial viability review of its Phase 2 program of FSD-201. 
  • In particular, the Company was concerned with the pace of advancement of the study when COVID-19 treatments evolved significantly and competitive products were being successfully advanced. 
  • Bloom Burton and the Company concluded that FSD-201 is unlikely to be commercially viable. 
  • Price Action: HUGE stock is down 11.10% at $1.53 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!